Atlas Trials

Yongsheng Wang

2 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Yongsheng Wang

RecordFirmDate
First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations (NCT07699952)Yongsheng Wang2026-09-09
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy (NCT05809024)Yongsheng Wang2023-03-01

Track Yongsheng Wang automatically

Every clearance here is in the API, with alerts when new ones post.